Afferent arteriolar vasodilator effect of adenosine predominantly involves adenosine A2B receptor activation.
Adenosine is an important paracrine agent regulating renal vascular tone via adenosine A(1) and A(2) receptors. While A(2B) receptor message and protein have been localized to preglomerular vessels, functional evidence on the role of A(2B) receptors in mediating the vasodilator action of adenosine on afferent arterioles is not available. The present study determined the role of A(2B) receptors in mediating the afferent arteriolar dilation and compared the effects of A(2B) and A(2A) receptor blockade on afferent arterioles. We used the rat in vitro blood-perfused juxtamedullary nephron technique combined with videomicroscopy. Single afferent arterioles of Sprague-Dawley rats were visualized and superfused with solutions containing adenosine or adenosine A(2) receptor agonist (CV-1808) along with adenosine A(2B) and A(2A) receptor blockers. Adenosine (10 micromol/l) caused modest constriction and subsequent superfusion with SCH-58261 (SCH), an A(2A) receptor blocker, at concentrations up 10 micromol/l elicited only slight additional decreases in afferent arteriolar diameter with maximum effect at a concentration of 1 micromol/l (-11.0 +/- 2.5%, n = 6, P < 0.05). However, superfusion of adenosine-treated vessels with MRS-1754 (MRS), an A(2B) receptor blocker, elicited greater decreases in afferent arteriolar diameter (-26.0 +/- 4.7%, n = 5, P < 0.01). SCH did not significantly augment the adenosine-mediated afferent constriction elicited by MRS; however, adding MRS after SCH caused further significant vasoconstriction. Superfusion with CV-1808 dilated afferent arterioles (17.2 +/- 2.4%, n = 6, P < 0.01). This effect was markedly attenuated by MRS (-22.6 +/- 2.0%, n = 5, P < 0.01) but only slightly reduced by SCH (-9.0 +/- 1.1%, n = 5, P < 0.05) and completely prevented by adding MRS after SCH (-24.7 +/- 1.8%, n = 5, P < 0.01). These results indicate that, while both A(2A) and A(2B) receptors are functionally expressed in juxtamedullary afferent arterioles, the powerful vasodilating action of adenosine predominantly involves A(2B) receptor activation, which counteracts A(1) receptor-mediated vasoconstriction.
Feng
Ming-Guo
MG
Department of Physiology, Hypertension and Renal Center of Excellence, Tulane University Medical Center, New Orleans, Louisiana, USA. mfeng@tulane.edu
Navar
L Gabriel
LG
D000081:Acetamides / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D058908:Adenosine A2 Receptor Agonists; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D001160:Arterioles / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007668:Kidney / Q000098:blood supply*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D018715:Microscopy, Video; D010477:Perfusion; D011687:Purines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043705:Receptor, Adenosine A2A / Q000378:metabolism; D043704:Receptor, Adenosine A2B / Q000378:metabolism*; D012079:Renal Circulation / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology; D014661:Vasoconstriction; D014664:Vasodilation / Q000187:drug effects
C098657:5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; D000081:Acetamides; D058908:Adenosine A2 Receptor Agonists; D058917:Adenosine A2 Receptor Antagonists; C423842:N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide; D011687:Purines; D011743:Pyrimidines; D043705:Receptor, Adenosine A2A; D043704:Receptor, Adenosine A2B; D014230:Triazoles; C026708:2-phenylaminoadenosine; D000241:Adenosine
Nephrol Dial Transplant. 2007 Oct;22(10):2805-9
17556415
Trends Pharmacol Sci. 1996 Oct;17(10):364-72
8979771
Hypertension. 2007 Oct;50(4):744-9
17664389
Mol Pharmacol. 1990 Nov;38(5):660-6
2172773
Am J Physiol Renal Physiol. 2006 Jul;291(1):F155-61
16478979
Kidney Int. 2009 Apr;75(8):793-9
19165174
J Pharmacol Exp Ther. 1996 Feb;276(2):398-404
8632302
Physiol Rev. 2006 Jul;86(3):901-40
16816141
Kidney Int. 2009 Apr;75(8):769-71
19337216
Am J Physiol Renal Physiol. 2002 Jul;283(1):F41-51
12060585
Curr Opin Nephrol Hypertens. 2003 Sep;12(5):497-502
12920396
Am J Physiol Renal Physiol. 2006 Apr;290(4):F888-91
16263804
Biochem Pharmacol. 2001 Feb 15;61(4):443-8
11226378
Am J Physiol. 1992 Dec;263(6 Pt 2):F991-5
1481890
Physiol Rev. 1996 Apr;76(2):425-536
8618962
Pharmacol Rev. 2001 Dec;53(4):527-52
11734617
Handb Exp Pharmacol. 2009;(193):443-70
19639291
Kidney Int. 2004 Apr;65(4):1180-90
15086457
Trends Pharmacol Sci. 1997 Mar;18(3):79-82
9133776
Am J Physiol Renal Physiol. 2006 Apr;290(4):F873-9
16263803
Circ Res. 1970 Mar;26(3):327-38
4313452
Circ Res. 1978 Sep;43(3):465-9
679428
Alcohol Clin Exp Res. 2007 Aug;31(8):1302-7
17550371
Mol Pharmacol. 2004 Mar;65(3):702-10
14978249
J Pharmacol Exp Ther. 2007 Aug;322(2):678-85
17494861
J Med Chem. 2000 Mar 23;43(6):1165-72
10737749
Circ Res. 1980 Mar;46(3):449-56
6101998
Am J Physiol. 1987 Apr;252(4 Pt 2):F678-82
3565578
Am J Physiol Renal Physiol. 2004 Feb;286(2):F331-7
14583435
Biochem Pharmacol. 2001 Mar 15;61(6):657-63
11266650
Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):133-44
17310264
Mol Pharmacol. 1992 Nov;42(5):765-72
1435751
J Physiol. 1998 Jul 1;510 ( Pt 1):321-30
9625888
Pharmacol Ther. 2000 Feb;85(2):55-75
10722120
J Neurochem. 1992 Mar;58(3):941-50
1738001
Br J Pharmacol. 1999 Jul;127(6):1399-405
10455289
Pancreas. 2002 Jan;24(1):75-82
11741185
Exp Nephrol. 2002;10(5-6):383-92
12381923
Exp Biol Med (Maywood). 2007 Jun;232(6):715-26
17526763
Hypertension. 1999 Jan;33(1 Pt 2):511-6
9931157
Circ Res. 1980 Jun;46(6 Pt 2):I175-82
6247089
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9983-8
11504952
Am J Physiol. 1982 May;242(5):F423-35
7044144
Br J Pharmacol. 2004 Feb;141(3):441-8
14718251
Am J Physiol Renal Physiol. 2001 Mar;280(3):F406-14
11181402
J Pharmacol Exp Ther. 2005 Dec;315(3):1150-7
16120812
J Med Chem. 2002 Jan 3;45(1):115-26
11754583